• Je něco špatně v tomto záznamu ?

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

K. Pavelka, Z. Szekanecz, N. Damjanov, B. Anić, M. Tomšič, V. Mazurov, M. Maksimovic, O. Nagy, J. Świerkot, T. Petranova, T. Veldi, A. Baranauskaitė, C. Codreanu, D. Andersone, R. Fleischmann,

. 2020 ; 9 (-) : . [pub] 20201019

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21001946

Background: In the randomized, phase III, global SELECT-COMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc analysis of SELECT-COMPARE reports the efficacy and safety of upadacitinib in Central and Eastern European (CEE) patients. Methods: Patients were randomized 2:2:1 to upadacitinib 15 mg once daily, placebo, or adalimumab 40 mg every other week, and continued MTX. Efficacy and safety were assessed through 48 weeks. Primary endpoints were the achievement of ≥20% improvement in American College of Rheumatology response criteria and Disease Activity Score in 28 joints with C-reactive protein <2.6 responses at week 12 for upadacitinib versus placebo. No statistical comparisons were conducted. Results: A total of 596 patients from 12 CEE countries were randomized. At week 12, a numerically greater proportion of patients receiving upadacitinib versus placebo or adalimumab achieved ≥20% improvement in American College of Rheumatology response criteria (72% versus 33% and 59%), Disease Activity Score in 28 joints with C-reactive protein <2.6 (26% versus 4% and 11%), low disease activity and remission, and improved physical function, with results maintained over 48 weeks. Upadacitinib treatment numerically inhibited structural progression versus placebo at week 26. Serious infection and herpes zoster rates were numerically higher with upadacitinib versus adalimumab (2.7 versus 1.7 and 2.3 versus 1.1 events/100 patient-years, respectively) over 48 weeks. Conclusion: Consistent with the global population of patients with rheumatoid arthritis and an inadequate response to MTX, in CEE patients, upadacitinib 15 mg demonstrated clinical and functional improvements versus placebo and adalimumab, radiographic improvements versus placebo, and reasonable safety, over 48 weeks.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001946
003      
CZ-PrNML
005      
20210126092836.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.7573/dic.2020-7-5 $2 doi
035    __
$a (PubMed)33123205
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Pavelka, Karel $u Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic.
245    10
$a Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. / $c K. Pavelka, Z. Szekanecz, N. Damjanov, B. Anić, M. Tomšič, V. Mazurov, M. Maksimovic, O. Nagy, J. Świerkot, T. Petranova, T. Veldi, A. Baranauskaitė, C. Codreanu, D. Andersone, R. Fleischmann,
520    9_
$a Background: In the randomized, phase III, global SELECT-COMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc analysis of SELECT-COMPARE reports the efficacy and safety of upadacitinib in Central and Eastern European (CEE) patients. Methods: Patients were randomized 2:2:1 to upadacitinib 15 mg once daily, placebo, or adalimumab 40 mg every other week, and continued MTX. Efficacy and safety were assessed through 48 weeks. Primary endpoints were the achievement of ≥20% improvement in American College of Rheumatology response criteria and Disease Activity Score in 28 joints with C-reactive protein <2.6 responses at week 12 for upadacitinib versus placebo. No statistical comparisons were conducted. Results: A total of 596 patients from 12 CEE countries were randomized. At week 12, a numerically greater proportion of patients receiving upadacitinib versus placebo or adalimumab achieved ≥20% improvement in American College of Rheumatology response criteria (72% versus 33% and 59%), Disease Activity Score in 28 joints with C-reactive protein <2.6 (26% versus 4% and 11%), low disease activity and remission, and improved physical function, with results maintained over 48 weeks. Upadacitinib treatment numerically inhibited structural progression versus placebo at week 26. Serious infection and herpes zoster rates were numerically higher with upadacitinib versus adalimumab (2.7 versus 1.7 and 2.3 versus 1.1 events/100 patient-years, respectively) over 48 weeks. Conclusion: Consistent with the global population of patients with rheumatoid arthritis and an inadequate response to MTX, in CEE patients, upadacitinib 15 mg demonstrated clinical and functional improvements versus placebo and adalimumab, radiographic improvements versus placebo, and reasonable safety, over 48 weeks.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Szekanecz, Zoltán $u Division of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
700    1_
$a Damjanov, Nemanja $u University of Belgrade School of Medicine, Institute of Rheumatology, Belgrade, Serbia.
700    1_
$a Anić, Branimir $u Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb School of Medicine, Zagreb, Croatia.
700    1_
$a Tomšič, Matija $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
700    1_
$a Mazurov, Vadim $u North-Western State Medical University named after I.I. Mechnikov, St Petersburg, Russia.
700    1_
$a Maksimovic, Marija $u AbbVie Biopharmaceuticals GmbH, Belgrade, Serbia.
700    1_
$a Nagy, Orsolya $u AbbVie Global Medical Affairs, Rheumatology, Budapest, Hungary.
700    1_
$a Świerkot, Jerzy $u Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
700    1_
$a Petranova, Tzvetanka $u Department of Rheumatology, UMHAT St.Iv.Rilsky, Medical University, Sofia, Bulgaria.
700    1_
$a Veldi, Tiina $u East-Tallinn Central Hospital, Tallinn, Estonia.
700    1_
$a Baranauskaitė, Asta $u Department of Rheumatology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
700    1_
$a Codreanu, Catalin $u Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania.
700    1_
$a Andersone, Daina $u P. Stradins Clinical University Hospital, Riga, Latvia.
700    1_
$a Fleischmann, Roy $u University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, USA.
773    0_
$w MED00190060 $t Drugs in context $x 1745-1981 $g Roč. 9, č. - (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33123205 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092832 $b ABA008
999    __
$a ind $b bmc $g 1614085 $s 1122230
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c - $e 20201019 $i 1745-1981 $m Drugs in context. $n Drugs Context $x MED00190060
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace